Malaria Soil-transmitted helminthiasis and Schistosomiasis
Conditions
Interventions
Amodiaquine plus sulphadoxinepyrimethamine plus albendazole and or praziquantel
Amodiaquine plus sulphadoxinepyrimethamine only
Sponsors
London School of Hygiene Tropical Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: • Male and female children aged 1-14 years; • Provision of a written informed consent by the parent/caregiver and a positive assent by children aged = 12 years (in line with legal regulations in Senegal); • Willingness to provide finger-prick blood samples, urine, and stool samples; • Residence in the study area for at least six months.
Exclusion criteria
Exclusion criteria: • Acutely ill child at the time of the drug administration; • Child whose parents/caregivers decline to provide consent; • A known HIV positive child receiving cotrimoxazole prophylaxis; • A child who has received a dose of either SP, AQ, ALB or PZQ during the previous six months; • A child with a known allergy to any of SP, AQ, ALB or PZQ.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| •All solicited and unsolicited adverse events and adverse drug reactions will be assessed for causal relationships to the study medications. | — |
Secondary
| Measure | Time frame |
|---|---|
| • Prevalence and intensity of Plasmodium-helminth co-infection o Faecal egg counts for each of the four parasites (hookworm, A. lumbricoides, T. trichiura, and S. mansoni) and urine egg count for S.haematobium will be recorded, and the prevalence and arithmetic mean intensity of infection, including both positive and negative individuals will be calculated, before and after co-administration of SMC and anthelminthic drugs • Prevalence of anaemia and mean haemoglobin concentration o Haemoglobin concentration of all children will be checked using HemoCue®, before and after co-administration of SMC and anthelminthic drugs | — |
Countries
Senegal
Contacts
Public ContactJean Louis Ndiaye
Professor
Outcome results
None listed